Antares Pharma — Investor Presentation (September 2016)
23 slides from Antares Pharma's investor presentation, Sep 14, 2016
Slide 1: September 2016 Investor Presentation
NASDAQ: ATRS Exhibit 99.1 September 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate
Slide 3: Antares Pharma: Specialty Pharmaceutical Company
Antares Pharma A Growing, Revenue Generating State-of-the-Art Specialty Pharmaceutical Company An Innovative Leader In Self-Administered Injection Technology Four Drug/Drug-Device Products FDA Approved Since 2012 (most recently Sumatriptan Injection USP) Two Additional Drug Device Combination Produc
Slide 4: Second Quarter 2016 Highlights
Second Quarter 2016 Highlights – Executing On Our Plans Strong financial results – Total product revenue increased 49% versus Q215 Antares and Teva announced the commercial availability of generic Imitrex® (sumatriptan injection USP) on June 27, 2016 OTREXUP™ revenue increased 14% versus Q215 and 15
Slide 5: Diverse Pipeline of Proprietary and Partnered Products
Diverse Pipeline of Proprietary and Partnered Products Product Overview Product Brand/Partner Device Drug Indications Development/ Approval Status Financial Consideration OTREXUP™ Vibex Methotrexate (MTX) RA; pJIA Psoriasis US launch 2014 Proprietary Product Sales Launched with in-house sales force
Slide 6: 2016 Potential Value Drivers
2016 Potential Value Drivers Sumatriptan mid-year launch by Teva Anticipate QuickShot® Testosterone NDA filing late 2016 Alliance Business progress: Makena® life cycle management collaboration with AMAG Growth of OTREXUP™ Continued progress on pipeline products (Exenatide, Teriparatide, Epinephrine)
Slide 7: Value Driver #1 – VIBEX Sumatriptan Launch
Value Driver #1 – VIBEX® Sumatriptan Launch December 15, 2015 FDA approval; 4mg & 6mg doses commercially available 6/27/16 Therapeutically Equivalent to Imitrex® STATdose addressing a ~$200 million* retail injectable market 50/50 profit split with Teva Antares produces final packaged product & sells
Slide 8: Injectable Sumatriptan Market Opportunity
Injectable Sumatriptan Market Opportunity Source: Symphony Health Solutions 2015 Retail PHAST Legacy 2.0 TRx Dollars, Auto/Pen Injector Market ~ $200 Million
Slide 9: Value Driver #2 – NDA Filing For QuickShot Testosterone
Value Driver #2 – NDA Filing For QuickShot® Testosterone NDA filing currently targeted for late Q416 Possible launch in late 2017 / early 2018 Final safety data from 52 week 003 study reported – most common included increased hematocrit, hypertension, upper respiratory tract infection, sinusitis, in
Slide 10: Testosterone Replacement Market: 2015-16 Retail Prescriptions
Testosterone Replacement Market: 2015-16 Retail Prescriptions 10 Symphony Health Solutions: Phast IDV 2016 2015
Slide 11: QST-13-003 Exceeded all Protocol-Required Outcomes
QST-13-003 Exceeded all Protocol-Required Outcomes1 Population/Analysis Cavg Lower limit of the 95% 2-sided C. I. C avg % in Range 300 – 1100 ng/dL n (%) Cmax <1500 ng/dL n (%) Cmax >1800 ng/dL n (%) Primary analysis* N=150 87.3% 139 (92.7%) 137 (91.3%)** 0% Completers N=137 94.8% 135 (98.5%) 137 (1
Slide 12: Value Driver #3 – Grow Alliance Business
Value Driver #3 – Grow Alliance Business AMAG Makena® alliance (began in 2014) Developing a subcutaneous auto injector device Better patient compliance Potentially less painful injection (small gauge needle) and easier administration Currently Makena® is ~ $250 million product opportunity, expected
Slide 13: Makena Life Cycle Program
Makena® Life Cycle Program Preservative free More convenient for HCPs More cost effective for insurers Approved 2/23/16, launched 4/4/16 Device partner Antares Issued & pending patents Potential for less painful injections sNDA estimated filing in 2Q17 with 10 month regulatory review Makena® subcuta
Slide 14: Value Driver #4 – OTREXUP Growth
Value Driver #4 – OTREXUP™ Growth First approved methotrexate for subcutaneous injection in the U.S. Single-use, disposable & easy to use Collar activated, no push button, easy to grip and virtually painless Needle guard prevents accidental sticks Audible click followed by red indicator to confirm i
Slide 15: OTREXUP Q216 Revenues
OTREXUP™ Q216 Revenues of $3.8 million were up 14% vs. Q215; and up 15% sequentially vs. Q116 Committed to growing OTREXUP™: Leadership changes in sales and marketing organizations Modifying certain payer tactics Take advantage of new interim dosage strengths that have recently been launched
Slide 16: Near Term Pipeline Opportunities
Near Term Pipeline Opportunities Epinephrine Auto Injector Exenatide Teriparatide 16
Slide 17: VIBEX Epinephrine Auto Injector
VIBEX® Epinephrine Auto Injector Teva filed ANDA amendment with FDA in December 2014, Complete Response Letter (CRL) issued February 2016, Teva and Antares working together to answer FDA questions Shipped $1.0 million in devices to Teva in Q216 and ~$17 million to date Agreement with Teva – ATRS wil
Slide 18: Generic Byetta (exenatide)
Generic Byetta® (exenatide) Teva announced settlement with AstraZeneca and Amylin which allows Teva to launch on October 15, 2017, pending FDA approval Teva filed ANDA in December 2014 and it is under review – Antares believes Teva has first to file status and 180 day marketing exclusivity Symphony
Slide 19: Generic Forteo (teriparatide)
Generic Forteo® (teriparatide) Teva ANDA accepted by FDA 2/16; Lilly filed a lawsuit in response to Teva’s Paragraph IV notice, 30 month stay expires in August 2018 Lilly has agreed not to sue Teva on the device patent (which expires in 2025) - last to expire patent is now August 2019* Based on avai
Slide 20: Second Quarter 2016 Revenue Mix
Second Quarter 2016 Revenue Mix Three Months Ended June 30 Increase 2016 2015 (Decrease) OTREXUP $ 3,810 $ 3,346 14% Auto injector and pen injector devices 3,914 1,769 121% Needle-free injector devices & components 966 725 33% Total Product Sales 8,690 5,840 49% Development revenue 3,267 3,027 8% Li
Slide 21: Second Quarter 2016 Financial Results
Second Quarter 2016 Financial Results Three Months Ended June 30 Increase 2016 2015 (Decrease) Total Revenue $ 12,228 $ 14,420 -15% Cost of Revenue 7,318 4,708 55% Gross Profit 4,910 9,712 -49% % Revenues 40% 67% Research & Development 3,948 4,569 -14% Selling, General & Administrative 7,014 6,605 6
Slide 22: Investment Considerations
Investment Considerations A growing, revenue generating company – $12.2 million in Q216 and $24.5 million through the six month period ended 6/30/16 Multiple development pipeline products targeting large therapeutic markets over the next five years Several potential value drivers in 2016: Sumatripta
Slide 23: Making medicines better
making medicines better Me antares pharma making medicines, better 7 antares feel? a
Antares Pharma — Investor Presentation (September 2016) on 6ix